Page 944 - Read Online

Caron de Fromentel et al. Hepatoma Res 2020;6:80 I http://dx.doi.org/10.20517/2394-5079.2020.77 Page 13 of 18

Copyright
© The Author(s) 2020.

REFERENCES
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer 2019;144:1941-53.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
3. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol
2018;15:599-616.
4. Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol
2020;72:209-14.
5. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N
Engl J Med 2020;382:1894-905.
6. Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms.
Semin Cancer Biol 2015;31:16-27.
7. Fekir K, Dubois-Pot-Schneider H, Désert R, et al. Retrodifferentiation of human tumor hepatocytes to stem cells leads to metabolic
reprogramming and chemoresistance. Cancer Res 2019;79:1869-83.
8. Barbato L, Bocchetti M, Di Biase A, Regad T. Cancer stem cells and targeting strategies. Cells 2019;8:926.
9. Philips GM, Chan IS, Swiderska M, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular
carcinoma in a murine model of primary liver cancer. PLoS One 2011;6:e23943.
10. Khosla R, Rastogi A, Ramakrishna G, et al. EpCAM+ liver cancer stem-like cells exhibiting autocrine wnt signaling potentially originate
in cirrhotic patients. Stem Cells Transl Med 2017;6:807-18.
11. Yang W, Yan HX, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.
Cancer Res 2008;68:4287-95.
12. Malfettone A, Soukupova J, Bertran E, et al. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in
hepatocellular carcinoma. Cancer Lett 2017;392:39-50.
13. Luo J, Wang P, Wang R, et al. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular
carcinoma. Oncotarget 2016;7:9525-37.
14. Della Corte CM, Viscardi G, Papaccio F, et al. Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol
2017;23:4330-40.
15. Kawai T, Yasuchika K, Ishii T, et al. Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma. Clin Cancer Res
2015;21:3081-91.
16. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280-1.
17. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell
features. Gastroenterology 2009;136:1012-24.
18. Levrero M, De Laurenzi V, Costanzo A, et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell
Sci 2000;113:1661-70.
19. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and
response to stress. Cell Death Differ 2006;13:962-72.
20. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004;61:822-
42.
21. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007;7:165-8.
22. Sauer M, Bretz AC, Beinoraviciute-Kellner R, et al. C-terminal diversity within the p53 family accounts for differences in DNA binding
and transcriptional activity. Nucleic Acids Res 2008;36:1900-12.
23. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J
Exp Med 1998;188:1763-8.
24. De Laurenzi VD, Catani MV, Terrinoni A, et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification
of two new splicing variants epsilon and zeta. Cell Death Differ 1999;6:389-90.
25. Courtois S, Caron de Fromentel C, Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms.
Oncogene 2004;23:631-8.
26. Costanzo A, Pediconi N, Narcisi A, et al. TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and
hierarchy. FEBS Lett 2014;588:2590-9.
27. Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol 2019;11:564-77.
28. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell 2017;170:1062-78.
29. El-Deiry WS. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res 2016;76:5189-91.
30. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
31. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour
suppression? Cell Death Differ 2018;25:104-13.
32. Crighton D, Wilkinson S, O’Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121-34.